NasdaqGM:ARCTBiotechs
Arcturus Therapeutics Holdings (ARCT) Q4 Loss Deepens To US$1.03 EPS Challenging Profitability Hopes
Arcturus Therapeutics Holdings (ARCT) closed FY 2025 with fourth quarter revenue of US$7.2 million and a basic EPS loss of US$1.03, while trailing 12 month revenue reached US$82.0 million alongside a basic EPS loss of US$2.40. Over recent quarters the company has seen revenue shift from US$41.7 million in Q3 2024 to US$29.4 million in Q1 2025, US$28.3 million in Q2 2025, US$17.2 million in Q3 2025 and US$7.2 million in Q4 2025, with quarterly basic EPS losses ranging between US$0.26 and...